• Explore /
  • Poster
  • / Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

Johanna C. Bendell , Bert H. O'Neil , Alexander Starodub , Derek J. Jonker , Thorvardur Ragnar Halfdanarson , William Jeffery Edenfield , Bassel F. El-Rayes , Joleen Marie Hubbard , Henry C. Pitot , Timothy J. Hobday , Youzhi Li , Yuan Gao , Axel Grothey , Laura Borodyansky , Chiang Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02024607

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 593)

DOI

10.1200/JCO.2017.35.4_suppl.593

Abstract #

593

Poster Bd #

D11

Abstract Disclosures

Similar Posters

First Author: Bert H. O'Neil

First Author: Joleen Marie Hubbard

First Author: Axel Grothey

First Author: Johanna C. Bendell